CC
ESPR

Centiva Capital’s Esperion Therapeutics ESPR Stock Holding History

Centiva Capital’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-7,500
Closed -$11.9K – 1720
2023
Q1 		$11.9K Buy
+7,500
New +$38.7K ﹤0.01% 1442

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return

Centiva Capital's ESPR Position: Q2 2023 in Review

Centiva Capital sold out of Esperion Therapeutics (ESPR) in Q2 2023, closing a stake of 11,117 shares — an estimated $17.7K sold.

Centiva Capital first reported a position in ESPR in Q3 2021 and held it in 2 quarters. The position peaked at $182K in Q3 2021. 124 funds tracked by Wall St. Rank hold ESPR as of Q2 2023.

  • Centiva Capital reported no remaining Esperion Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Centiva Capital sold 11,117 Esperion Therapeutics shares in Q2 2023, an estimated $17.7K.
  • Centiva Capital first reported a position in Esperion Therapeutics in Q3 2021 and held it in 2 quarters.
  • Centiva Capital's Esperion Therapeutics position peaked at $182K in Q3 2021.
  • 124 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2023.

Based on Centiva Capital's 13F filing for Q2 2023, filed 14 Aug 2023.